OBI Pharma Announces Acquisition of TH-3424 from Threshold Pharmaceuticals

OBI Pharma to develop OBI-3424 (previously TH-3424) as a potential treatment of cancers expressing AKR1C3. Taipei, Taiwan, June 1, 2017 — OBI Pharma, Inc., a Taiwan biopharma company (TPex: 4174), announced today an agreement with Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) to acquire TH-3424, a first-in-class novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme […]

This article is password protected.

To view the content, please enter your password in the field below